David Hutton

According to researchers at the University of Virginia School of Medicine, common HIV drugs or a safer alternative could stop vision loss.

Ophthalmologists and industry executives share what lingers on their minds at the end of the day.

The screening device works by assessing the eyes’ ability to fixate together. Held 14 inches from the eyes, the child fixates on a smiley face while the device simultaneously scans both retinas.

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab.

In the weeks leading up to the October awareness day, the International Agency for the Prevention of Blindness has revealed a campaign to encourage one million people to pledge to have a vision test.

Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.

Orbis, with support from FedEx, is offering training that will develop ophthalmologists’ skills to treat diabetic retinopathy in China.

Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.

The eyeglasses were reportedly designed to help the wearer reach enlightenment and drive away evil, according to Sotheby’s London, which will host the auction next month.

Bath, who invented the Laserphaco Probe for treating cataracts, is the first African-American woman inducted into the National Inventors Hall of Fame.

Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.

Investigators are working on the development of an intranasal subunit vaccine that provides durable local immunity against inhaled pathogens.

The organization’s policies come amid federal mandates designed to spur Americans who are not vaccinated against COVID-19 to get a shot.

TearLab, MellingMedical reach an agreement to enhance early detection of dry eye disease in veterans.

A team of investigators have found that a molecular mechanism drives the progression of uveal melanoma, an often lethal eye cancer in adults.

Investigators at Dartmouth College have found that eye contact during a conversation makes the discussion more appealing to its participants.

Children’s Hospital of Philadelphia and Stanford University School of Medicine will lead the $5.4 million study ,with patient recruitment beginning in late 2021 or early 2022.

AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.

Carel B. Hoyng, MD, discusses his presenation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

Despite varied results, the company will submit a New Drug Application for pegcetacoplan for geographic atrophy to the FDA early next year.

OD-OS’s teleguidance offering addresses the lack of experts and also benefits teaching in retina laser care.

The gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year.

TearClear to start clinical trial for TC-002 latanoprost ophthalmic solution 0.005%.

Amid a surging COVID-19 pandemic, ophthalmologists in the path of Hurricane Ida are now dealing with the storm's impact.

According to the Academy and RPB, the grant recipients will use the IRIS Registry database to improve the diagnosis and treatment of eye disease.

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

Led by eye care nonprofit Orbis with support from Alcon, the training will build eye care professionals' skills to treat retinopathy of prematurity in Latin America

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

According to McKinsey’s Hospital Insights Survey, hospital outpatient and procedural volumes were nearly 4 percent higher in July compared to 2019, but ophthalmology was down during the same period.

Sight Sciences reveals real-world data that show the safety, efficacy, and durability of effect of its Omni Surgical System for use in a standalone procedure to reduce IOP and medication burden.